目的 探討美托洛爾和卡維地洛對非ST段抬高型心肌梗死（NSTEMI）患者結局及γ-谷氨酰轉移酶（GGT）、尿酸的影響。方法 前瞻性納入120例NSTEMI患者，按用藥不同將患者分為美托洛爾組（n=60）和卡維地洛組（n=60），分別給予琥珀酸美托洛爾緩釋片47.5 mg，每日1次；卡維地洛片25 mg，每次12.5 mg，每日2次。兩組均治療3個月。此后，所有患者均接受冠狀動脈造影，并進行為期12個月的隨訪。于入院后、造影后第1個月和第3個月抽血并檢測GGT和尿酸。結果 兩組患者住院時GGT和UA水平比較均無統(tǒng)計學差異；冠脈造影1、3月后復查，兩組患者GGT和UA水平均顯著低于入院時（P<0.05），但兩組間比較仍均無統(tǒng)計學差異。此外，卡維地洛組患者主要終點總不良事件發(fā)生率顯著低于美托洛爾組，差異有統(tǒng)計學意義（P<0.05）。結論 美托洛爾和卡維地洛沒有降低NSTEMI患者GGT和尿酸水平；給予NSTEMI患者卡維地洛者短期結局優(yōu)于美托洛爾。

Objective To investigate the effects of metoprolol and carvedilol on outcome and γ-glutamyltransferase (GGT) and uric acid in patients with non-ST-elevation myocardial infarction (NSTEMI). Methods Patients were enrolled in 120 patients with NSTEMI who were divided into metoprolol (n=60) and carvedilol (n=60) according to prospective randomized controlled trial. All patients were given coronary artery angiography, and for a period of 12 months follow-up. After admission, blood was collected from the first and third months after angiography and GGT and uric acid were measured. Results There was no significant difference in GGT and uric acid levels between the first and third months after admission. There was no significant difference between the patients in the carvedilol group and the carvedilol group The incidence of adverse events was significantly lower than in the metoprolol group in the primary end point (P < 0.05). Conclusion Metoprolol and carvedilol did not reduce GGT and uric acid levels in NSTEMI patients; the short-term outcome of carvedilol given to patients with NSTEMI was superior to metoprolol.